Humana (NYSE:HUM – Get Rating) had its price objective boosted by Barclays from $500.00 to $570.00 in a research note issued to investors on Thursday morning, The Fly reports. Barclays currently has a maintains rating on the insurance provider’s stock.
Several other equities analysts have also recently weighed in on HUM. Mizuho lifted their price target on Humana from $500.00 to $529.00 and gave the company a maintains rating in a research report on Thursday. Truist Financial lifted their price target on Humana from $490.00 to $550.00 and gave the company a hold rating in a research report on Thursday, July 14th. Sanford C. Bernstein assumed coverage on Humana in a research report on Thursday, May 26th. They issued a market perform rating and a $506.00 price target for the company. Credit Suisse Group set a $548.00 price target on Humana in a research report on Tuesday, July 19th. Finally, Oppenheimer lifted their price target on Humana from $510.00 to $520.00 and gave the company an outperform rating in a research report on Thursday. Five research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of Moderate Buy and an average target price of $511.44.
Humana Stock Performance
NYSE:HUM opened at $482.00 on Thursday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.53 and a quick ratio of 1.53. The business has a fifty day simple moving average of $462.13 and a two-hundred day simple moving average of $440.76. Humana has a 1 year low of $351.20 and a 1 year high of $497.47. The company has a market capitalization of $60.97 billion, a P/E ratio of 20.45, a P/E/G ratio of 1.42 and a beta of 0.80.
In other news, insider Samir Deshpande sold 3,957 shares of the business’s stock in a transaction dated Tuesday, May 3rd. The stock was sold at an average price of $434.19, for a total value of $1,718,089.83. Following the completion of the sale, the insider now owns 5,529 shares of the company’s stock, valued at approximately $2,400,636.51. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.39% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Humana
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. raised its position in Humana by 4.4% during the 1st quarter. BlackRock Inc. now owns 11,751,892 shares of the insurance provider’s stock valued at $5,114,071,000 after purchasing an additional 497,536 shares during the last quarter. Vanguard Group Inc. raised its position in Humana by 9.2% during the 1st quarter. Vanguard Group Inc. now owns 10,927,647 shares of the insurance provider’s stock valued at $4,755,384,000 after purchasing an additional 919,325 shares during the last quarter. Wellington Management Group LLP raised its position in Humana by 38.8% during the 1st quarter. Wellington Management Group LLP now owns 8,775,376 shares of the insurance provider’s stock valued at $3,818,781,000 after purchasing an additional 2,453,565 shares during the last quarter. State Street Corp raised its position in Humana by 0.3% during the 4th quarter. State Street Corp now owns 5,726,024 shares of the insurance provider’s stock valued at $2,660,025,000 after purchasing an additional 15,994 shares during the last quarter. Finally, Capital Research Global Investors raised its position in Humana by 7.6% during the 1st quarter. Capital Research Global Investors now owns 4,164,456 shares of the insurance provider’s stock valued at $1,812,264,000 after purchasing an additional 292,456 shares during the last quarter. Institutional investors own 94.93% of the company’s stock.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
- Get a free copy of the StockNews.com research report on Humana (HUM)
- Use These To Find Your Stock’s Support and Resistance Levels
- Is Boeing Stock is Ready for Lift-Off ?
- Elon Musk is Out, But Should You Be In Twitter Stock?
- 3 Earnings Announcements That Could Surprise
- Twitter’s Up For Third Week In A Row: What’s Next For The Stock?
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.